1. Home
  2. MATH vs ALXO Comparison

MATH vs ALXO Comparison

Compare MATH & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metalpha Technology Holding Limited

MATH

Metalpha Technology Holding Limited

HOLD

Current Price

$1.17

Market Cap

53.8M

Sector

Finance

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$2.09

Market Cap

68.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MATH
ALXO
Founded
2015
2015
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.8M
68.3M
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
MATH
ALXO
Price
$1.17
$2.09
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$3.00
AVG Volume (30 Days)
44.9K
687.4K
Earning Date
01-01-0001
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
26.36
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.10
$0.41
52 Week High
$4.17
$2.66

Technical Indicators

Market Signals
Indicator
MATH
ALXO
Relative Strength Index (RSI) 34.61 50.14
Support Level $1.10 $2.01
Resistance Level $3.16 $2.31
Average True Range (ATR) 0.07 0.17
MACD 0.03 -0.03
Stochastic Oscillator 20.00 35.15

Price Performance

Historical Comparison
MATH
ALXO

About MATH Metalpha Technology Holding Limited

Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: